Sanofi Drug Shows Long-Term Benefit in Rare Disease

Indolent systemic mastocytosis is a rare disorder caused by the body producing too many mast cells, a type of immune cell. This buildup can occur in the skin, bone marrow, and digestive tract, leading to a wide range of debilitating symptoms like rashes, gastrointestinal issues, and severe allergic reactions. In approximately 95% of cases, the disease is driven by a specific genetic mutation known as KIT D816V. This mutation causes mast cells to activate improperly and accumulate in organs where they normally wouldn't be found in large numbers. AYVAKIT (avapritinib) is a precision therapy designed as a kinase inhibitor that potently and selectively targets the KIT D816V mutation. By blocking this specific molecular driver, the drug inhibits the proliferation and activation of the abnormal mast cells that cause the disease's symptoms. The U.S. Food and Drug Administration (FDA) first approved avapritinib for advanced systemic mastocytosis in June 2021. Its approval was expanded in May 2023 to include indolent systemic mastocytosis, making it the first and only therapy specifically approved for this more common form of the disease. The approval for indolent systemic mastocytosis was based on the PIONEER clinical trial. In that study, patients taking AYVAKIT showed a statistically significant and clinically meaningful reduction in their total symptom scores compared to those on placebo. Blueprint Medicines, the original developer of AYVAKIT, was acquired by Sanofi in a deal valued at approximately $9.1 billion, which was completed in July 2025. The acquisition was part of Sanofi's strategy to expand its portfolio in rare immunological diseases.